EPTIS
BAM Logo

LGC -Clinical Microbiology Laboratory Scheme - CLS

EPTIS factsheet 523995 | Last revision 2018-11-09 | URL: https://www.eptis.bam.de/pts523995 https://www.eptis.bam.de/pts523995

PT provider
PT provider LGC Standards Proficiency Testing LGC Standards Proficiency Testing
Based in United Kingdom
Language(s)
Remarks The primary aim of the Clinical Microbiology Laboratory proficiency testing scheme (CLS) is to enable laboratories performing the microbiological analysis of clinical samples to monitor their performance and compare it with that of their peers. The CLS scheme also aims to provide information to participants on technical issues and methodologies relating to Clinical Microbiology. The CLS scheme year operates from January to December. Further information about CLS, including test material availability, round despatch dates and reporting deadlines, are available on the current CLS application form. The operation of the scheme is supported by an Advisory Group consisting of experts in the field of Clinical Microbiology. The scheme is run in collaboration with the American Proficiency Institute (API). The scheme reports on the performance of U.K. participants to the National Quality Assurance Advisory Panel for Medical Microbiology.
Keywords
Product groups Animal test material
Human test material
Testing fields Biology
Medical analysis
Microbiology
Technical details
Test item Tested property Testing method
Simulated respiratory samples containing chemically modified, non-infectious bacterial cells Bordetella pertussis -
Bordetella parapertussis -
Simulated faecal samples containing heat inactivated C. difficile C. difficile Toxin -
C. difficile Antigen -
Simulated genital/urinary samples in specimen transport media containing non-infectious bacterial cells Chlamydia trachomatis -
Neisseria gonorrhoeae -
Simulated patient cultures from various sources containing lyophilized bacteria on swabs and/or a lyophilized pellet with diluent Blood culture ID -
Blood culture susceptibility -
CSF culture ID -
CSF culture susceptibility -
Ear/Eye culture ID -
Group B Strep culture -
N. gonorrhoeae culture -
Sputum culture ID -
Sputum culture susceptibility -
Stool culture ID -
Throat culture ID -
Urine colony count -
Urine culture ID -
Urine culture susceptibility -
Wound culture ID -
Wound culture susceptibility -
Virtual images of Gram stained smears from various patient sources Gram Stain Interpretation -
Leukocytes -
Stain Quality -
Sputum Specimen Quality -
Virtual images of Gram stained patient vaginal smears Bacterial vaginosis -
Nugent Score -
Simulated genital samples containing lyophilized bacteria on a swab Group B Strep culture -
Simulated urine samples containing heat inactivated Legionella pneumophila Legionella pneumophila Antigen -
Simulated patient samples containing lyophilized bacteria on a swab Methicillin-Resistant Staphylococcus aureus culture -
Methicillin-Resistant Staphylococcus aureus -
Staphylococcus Aureus -
Simulated nasopharyngeal washings with chemically modified, non-infectious bacterial cells. Mycoplasma pneumoniae -
Simulated urine samples containing heat inactivated Streptococcus pneumoniae Streptococcus pneumoniae Antigen -
Simulated patient throat swabs containing lyophilized bacteria. Group A Strep -
Group C/G Strep -
Vancomycin-Resistant Enterococcus Culture isolation and identification
Simulated patient samples containing lyophilized bacteria on a swab. Vancomycin-Resistant Enterococcus Molecular
Formalin fixed bacterial and/or mycobacterial organisms dried on a glass slide Acid Fast Bacilli Smear -
Simulated sputum samples with chemically modified, non-infectious bacterial cells Mycobacterium tuberculosis complex -
Rifampin resistance -
Simulated patient samples from various sources containing mycobacteria in liquid samples and/or lyophilized on loops Mycobacteriology culture ID Culture isolation and identification
Simulated patient cultures containing fungus, yeast and aerobic actinomycetes lyophilized on swab Mycology culture ID Culture isolation and identification
Giemsa stained thick and/or thin patient blood smears containing various blood parasites Blood parasite ID Microscopic identification
Simulated genital samples in transport media with stabilised microorganisms. Trichomonas vaginalis Antigen or Molecular
Simulated cervical samples with chemically modified, non-infectious virus cells. HPV -
HPV genotyping -
Simulated nasopharyngeal samples containing inactivated virus in storage buffer RSV Antigen -
Influenza A Antigen -
Influenza B Antigen -
Influenza A or B Antigen -
Adenovirus Antigen -
Simulated faecal samples containing inactivated rotavirus in storage buffer. Rotavirus Antigen -
Simulated blood cultures with chemically modified, non-infectious bacterial and fungal cells. Acinetobacter sp. -
Acinetobacter baumannii -
Citrobacter sp. -
Enterobacteriaceae -
Enterobacter sp. -
Enterobacter cloacae complex -
Enterococcus sp. -
Enterococcus faecalis -
Enterococcus faecium -
Escherichia coli -
Haemophilus influenzae -
Klebsiella oxytoca -
Klebsiella pneumoniae -
Listeria sp. -
Listeria monocytogenes -
Neisseria meningitidis -
Proteus sp. -
Pseudomonas aeruginosa -
Serratia marcescens -
Staphylococcus sp. -
Staphylococcus aureus -
Staphylococcus epidermidis -
Staphylococcus lugdunensis -
Streptococcus sp -
Streptococcus agalactiae -
Streptococcus anginosus group -
Streptococcus pneumoniae -
Streptococcus pyogenes -
Candida albicans -
Candida glabrata -
Candida krusei -
Candida parapsilosis -
Candida tropicalis -
Resistance Gene: mecA -
Resistance Gene: vanA/B -
Resistance Gene: vanA -
Resistance Gene: vanB -
Resistance Gene: KPC -
Resistance Gene: CTX-M -
Resistance Gene: IMP -
Resistance Gene: NDM -
Resistance Gene: OXA -
Resistance Gene: VIM -
Simulated faecal samples with chemically modified, non-infectious bacterial and parasitic cells and intact viral particles Campylobacter sp -
C. difficile toxin A/B -
Enteroaggregative E. coli (EAEC) -
Enteropathogenic E. coli (EPEC) -
Enterotoxigenic E. coli (ETEC)lt/st -
E. coli O157 -
Plesiomonas shigelloides -
Salmonella -
Shigella -
Shiga-like toxin producing E. coli (STEC) stx1/stx2 -
Shigella / Enteroinvasive E. coli (EIEC) -
Shiga Toxin 1 -
Shiga Toxin 2 -
Vibrio -
Vibrio cholerae -
Yersinia enterocolitica -
Cryptosporidium -
Cyclospora cayetanensis -
Entamoeba histolytica -
Giardia lamblia -
Adenovirus F 40/41 -
Astrovirus -
Norovirus GI/GII -
Rotavirus A -
Sapovirus -
Simulated CSF with chemically modified, non-infectious bacterial and fungal cells and intact viral particles Escherichia coli K1 -
Listeria monocytogenes -
Neisseria meningitidis -
Streptococcus agalactiae -
Streptococcus pneumoniae -
Cytomegalovirus -
Enterovirus -
Herpes simplex virus 1 -
Herpes simplex virus 2 -
Human herpes virus 6 -
Human parechovirus -
Varicella zoster virus -
Cryptococcus neoformans/gatti -
Simulated nasopharyngeal washings with chemically modified, non-infectious bacterial cells and intact viral particles Bordetella holmesii -
Bordetella pertussis -
B. parapertussis/ bronchiseptica -
Chlamydophila pneumoniae -
Mycoplasma pneumoniae -
Adenovirus -
Coronavirus -
Coronavirus 229E -
Coronavirus HKU1 -
Coronavirus NL63 -
Coronavirus OC43 -
Human Metapneumovirus (hMPV) -
Human Rhinovirus / Enterovirus -
Influenza A -
Influenza A H1 -
Influenza A H3 -
Influenza A / H1-2009 -
Influenza B -
Parainfluenza 1,2,3,4 -
Respiratory Syncytial Virus -
RSV A,B -
Rhinovirus -
Aims of the PT scheme
Target group of participants
Linked to specific legislation / standards
Additional, subsidiary aims validation of testing methods
Number of participants
Accredited or otherwise reviewed by a 3rd party
Operation is commissioned / requested by
Fees and frequency
Participation fee Fees vary according to selection from available groups.
Regularly operated Yes (12 rounds per year)
Year of first operation 2018
Contact details of the PT provider
Provider Contact person
LGC Standards Proficiency Testing
1 Chamberhall Business Park, Chamberhall Green,
BL9 0AP Bury Lancashire
United Kingdom

Phone: +44 (0)161 762 2500
Fax: +44 (0)161 762 2501
Web: http://www.lgcstandards.com http://www.lgcstandards.com
Mr Savvas Xystouris
Phone: +44 (0)161 762 2500
Fax: +44 (0)161 762 2501
Email: savvas.xystouris@lgcgroup.com savvas.xystouris@lgcgroup.com
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom, Mr Savvas Xystouris. Mr Savvas Xystouris.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.21